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ic resonance imaging (MRI), and mutational screening for 
the growth hormone-1 gene  (GH1) and the GHRH receptor 
gene  (GHRHR) in isolated GHD (IGHD), and  HESX1 ,  PROP1 , 
 POU1F1 ,  LHX3 ,  LHX4 , and  GLI2 in multiple pituitary hormone 
deficiency (MPHD) patients.  Results: GH was started at a 
height SDS of –3.2 ± 1.4 in IGHD patients and of –4.1 ± 2.1 in 
MPHD patients. Relative height gain was 0.3 SDS/year, abso-
lute gain 1.6 SDS, and 1.2/2.6 SDS in IGHD/MPHD, respec-
tively. Mid-parental target height was reached in 77%. Initial 
height SDS, bone age retardation and duration of GH re-
placement were correlated with height SDS gain. GHD per-
sisted into adulthood in 19 and 89% of subjects with IGHD 
and MPHD, respectively. In 1/42 IGHD patients a  GH1 mu-
tation was detected;  PROP1 mutations were found in 3/7 
MPHD subjects. Anterior pituitary hypoplasia, combined 
with posterior pituitary ectopy and pituitary stalk invisibility 
on MRI, was an exclusive finding in MPHD patients.  Conclu-
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 Abstract 
 Background: Growth hormone (GH) has been used to treat 
children with GH deficiency (GHD) since 1966.  Aims: Using a 
combined retrospective and cross-sectional approach, we 
explored the long-term outcomes of patients with GHD, an-
alysed factors influencing therapeutic response, determined 
persistence into adulthood, investigated pituitary morphol-
ogy, and screened for mutations in causative genes.  Meth-
ods: The files of 96 GH-deficient children were reviewed. In 
a subset of 50 patients, re-assessment in adulthood was per-
formed, including GHRH-arginine testing, pituitary magnet-
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sions: GH replacement successfully corrects the growth def-
icit in children with GHD. While the genetic aetiology re-
mains undefined in most cases of IGHD,  PROP1 mutations 
constitute a major cause for MPHD. Persistence of GHD into 
adulthood is related to abnormal pituitary morphology. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Pituitary-derived growth hormone (pGH) has been 
used to correct the growth deficit in children with GH 
deficiency (GHD) since 1969; recombinant GH (rGH) 
has been applied since 1985.
 In the past, assessment of GHD persistence into adult-
hood after attainment of final height was not performed 
systematically; GH substitution was discontinued as soon 
as the child reached near-final height. However, accord-
ing to paediatric endocrine consensus guidelines  [1, 2] , 
severe GHD constitutes an indication for lifelong substi-
tution because GH exerts beneficial effects on bone min-
eral density, muscle mass, body composition and well-
being. Magnetic resonance imaging (MRI) or computed 
tomography (CT) pituitary imaging techniques have sig-
nificantly improved in the past decades, and mutation 
analyses of genes known to cause GHD have become 
available. Isolated GHD (IGHD) is either sporadic or 
clusters in families, suggesting a genetic aetiology. To 
date, mutations in the growth hormone-1 gene  (GH1) 
and in the GHRH receptor gene  (GHRHR) have been 
identified in IGHD patients  [3] . In congenital multiple 
pituitary hormone deficiency (MPHD), genes encoding 
transcription factors, essential for pituitary differentia-
tion including  HESX1 ,  PROP1 ,  POU1F1 ,  LHX3 ,  GLI2 and 
 LHX4 , may be involved  [3] .
 Here we review data from our 40-year experience with 
GH treatment in order to retrospectively explore the 
long-term outcomes of our patients with GHD. Specifi-
cally, we investigated final height and height gain achieved 
by GH and analysed factors influencing therapeutic out-
come, including parental height, anthropometric birth 
data, chronologic age, height SDS and bone age at diag-
nosis, age at onset of puberty, GH preparations used and 
duration of GH replacement. By an additional cross-sec-
tional approach with re-assessment of a subset of pa-
tients during young adulthood, we determined final adult 
height and the rate of severe GHD persistence, investi-
gated pituitary morphology by imaging, and screened for 
mutations within genes known to be associated with 
IGHD and MPHD.
 Patients and Methods 
 The files of patients who were started on GH treatment for 
GHD and other pathologies between 1966 and 2000 in the Paedi-
atric Endocrine Department of the University Children’s Hospital 
Dresden, Germany were reviewed. One hundred and twelve pa-
tient data sets were available, 96 with complete data. Seventy-eight 
of these patients had been diagnosed with IGHD [18 with total 
IGHD, 43 with partial IGHD, 17 with neurosecretory dysfunction 
(NSD)] and 22 with MPHD (for definitions of these conditions, 
see ‘Definitions of Subcategories of IGHD’). All patients with 
GHD were invited for re-assessment in adulthood. Fifty-six (38 
male, 18 female) adult patients re-attended our outpatient clinic 
during 2008–2009. Fifty GHD patients, 42 with IGHD and 8 with 
MPHD, were clinically re-investigated.
 Retrospective data analysis, combined with clinical and labora-
tory workup and pituitary imaging at re-assessment, was per-
formed, including dynamic GHRH-arginine testing and muta-
tional analyses.
 Definitions of Subcategories of IGHD 
 The diagnosis of GHD in children with short stature for age and 
low serum IGF-1 and IGF-binding protein-3 concentrations had 
been confirmed using two standard dynamic tests, but due to the 
long time span, different tests (exercise test, clonidine test, insulin-
induced hypoglycaemia, arginine test) and different commercial 
kits were used.  Partial IGHD was diagnosed with a peak GH con-
centration of <10 ng/ml (450 pmol/l) but >5 ng/ml (225 pmol/l) in 
at least one dynamic test, in combination with a second test with 
similar or lower GH peaks.  Total IGHD was diagnosed if peak GH 
concentrations were <5 ng/ml (225 pmol/l) in two provocation 
tests.  NSD was assessed (in patients with normal GH peaks in two 
standard dynamic tests) via GH pulse analysis in blood samples, 
each continuously collected over 20 min during 10 h at nighttime 
(8 p.m. to 6 a.m.) using the PULSAR ® software (Pulsar Process 
Measurement Ltd., Malvern, UK). NSD was defined as an abnor-
mal 10-hour GH secretory profile [reduced number of GH pulses 
<4/night and reduced mean GH secretion (<3.6 nmol/l) due to 
reduced peak amplitudes].
 Definition of MPHD 
 The term MPHD was applied for patients with more than one 
pituitary hormone deficiency in addition to GHD.
 Retrospective Data Analysis 
 Past medical history included birth data, age at diagnosis of 
GHD, data on dynamic testing, duration of GH replacement, 
growth chart data, therapeutic measures concerning associated 
hormone deficiencies, and data on pubertal onset and parental 
height.
 GH Dosage 
 GH was initiated at 0.025 mg/kg body weight per day and ap-
plied via daily subcutaneous injections ( ∼ 0.18 mg/kg/week) and 
adapted according to IGF-1 levels and response in terms of height 
velocity or change in height SDS.
 SDS Scores, Bone Age and Parental Target Height 
 For comparison with the normal population, height and weight 
data were quantified as SDS scores using the references from Pra-
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der et al.  [4] . Bone age was determined according to the method of 
Greulich and Pyle  [5] . Parental target height (TH) was calculated 
using the formula TH = (maternal height + paternal height)/2 + 
6.5 cm for boys and – 6.5 cm for girls, with a standard deviation 
(SD) of 7 cm for boys and 5.5 cm for girls  [6] .
 Workup at Re-Assessment during Adulthood 
 A thorough clinical examination and unstimulated pituitary 
function tests were performed. Blood samples were analysed with 
regard to IGF-1, IGF-binding protein-3, cortisol, TSH, T 3 , free T 4 , 
LH, FSH, testosterone, estradiol and prolactin levels. If low IGF-1 
levels were found (<–2 SDS), the function of the somatotrophs 
was additionally re-evaluated using GHRH-arginine as a standard 
dynamic GH stimulation test, with a cutoff of 3 ng/ml (225 pmol/l) 
for diagnosis of severe adult GHD. Hormones were measured us-
ing commercial chemiluminescence and immunoradiometric as-
says. All methods were quality-controlled and accredited accord-
ing to international standards. Pituitary MRI (1.5 T, Siemens 
Avanto; Siemens, Munich, Germany) was performed in patients 
without previous imaging and in all patients with MPHD, includ-
ing high-resolution pituitary imaging through the hypothalamo-
pituitary region. Molecular genetic screening for mutations with-
in the  GH1 and  GHRHR genes was performed in subjects with 
IGHD. Sequence analysis of genes coding for pituitary transcrip-
tion factors  (HESX1, PROP1, POU1F1, LHX3, LHX4, GLI2) was 
undertaken in patients with additional pituitary hormone defi-
ciencies, excluding patients with transfusional iron overload. Ge-
netic testing was performed using previously published methods 
 [7] . Sequences of primers will be provided by the authors on re-
quest.
 Ethics 
 Informed written consent was obtained for all procedures from 
all patients at re-evaluation. The study was approved by the local 
ethics committee of the Medical Faculty, Technische Universität 
Dresden, Germany (approval number: EK47032008).
 Statistics 
 Statistical analysis and drafting of figures was performed using 
GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, Calif., 
USA) and SPSS 15.0.1 (IBM SPSS Inc., New York, N.Y., USA). All 
results are expressed as mean ± SD unless otherwise indicated. 
Where normality of distribution was determined by the Kol-
mogorov-Smirnov test, t tests for independent samples were con-
ducted, otherwise the Mann-Whitney U test was used. Depen-
dence between two variables was assessed using Pearson’s correla-
tion coefficient. Significance was defined as a p value <0.05.
 Results 
 Long-Term Outcomes of GH Replacement 
 Ninety-six (68 male, 28 female) patients were started 
on GH treatment at a height SDS of –3.2 ± 1.4 for IGHD 
patients (n = 75) and of –4.1 ± 2.1 for MPHD patients 
(n = 21). In boys (n = 63), GH was replaced over 6.0 ± 
4.1 years, from age 11.2 ± 3.3 years up to age 17.5 ± 3.2 
years. Girls (n = 25) were treated over 4.3 ± 2.4 years, 
from age 10.8 ± 2.8 years to age 15.5 ± 1.9 years. Mean 
relative height gain was 0.3/0.31 SDS per year of GH 
treatment in boys/girls, and 0.3 SDS/year in IGHD and 
MPHD patients, respectively. Boys and girls gained 1.6 
SDS ( fig. 1 ), IGHD patients 1.2 SDS and MPHD patients 
2.6 SDS (p = 0.003), with GH replaced for 4.6 ± 2.8 years 
in IGHD patients and for 9.1 ± 4.9 years in MPHD pa-
tients.
 Thirty-eight male and 12 female patients underwent 
re-assessment at a mean age of 27 years (range 19–57 
years). After termination of GH substitution, boys and 
girls had gained a further 0.2 SDS of height on average. 
The outcomes in the subsets of IGHD patients, i.e. total 
IGHD, partial IGHD and NSD, are detailed in  table  1 . 
Males’ final height was 170 ± 10 cm (–1.3 SDS), females’ 
final height 156 ± 7 cm (–1.5 SDS). Final height was in the 
range of or above the individual parental TH in 54/70 
(77%) patients and below it in 16/70 (23%). IGHD pa-
tients reached TH in 81% (44/54), MPHD patients in 63% 
(10/16) ( fig. 2 ). The mean parental TH of GH-deficient 
2
1
0
–1
–2
–3
–4
–5
–6
–7
–8
–9
–10
n = 68
–2.9
n = 61
Male
–1.3
n = 50
–1.1
n = 28
–3.4
n = 25
Female
H
ei
gh
t S
D
S
–1.8
n = 19
Final height SDS
Height SDS at end of therapy
Height SDS at start of therapy
–1.5
 Fig. 1. Course of height SDS of boys and girls with GHD (at the 
start of GH therapy, at the end of replacement and final height 
SDS). The mean absolute height gain on GH was 1.6 SDS in boys 
and in girls. 
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All patients with GHD MPHD  IGHD Statistical test
(MPHD vs. IGHD)total partial NSD
Age at diagnosis of GHD, years (mean ± SD)
Male 11.2 ± 3.3
(n = 71)
9.6 ± 4.1
(n = 16)
12.1 ± 4.2
(n = 14)
11.5 ± 2.3
(n = 30)
11.4 ± 2.5
(n = 11)
p = 0.078
Mann-Whitney U test
nMPHD = 21
nIGHD = 78
Female 10.8 ± 2.8
(n = 28)
11.3 ± 2.9
(n = 5)
9.4 ± 5.5
(n = 4)
11.2 ± 2.4
(n = 13)
10.4 ± 1.7
(n = 6)
Bone age retardation at diagnosis, years (mean ± SD)
Male 3.3 ± 1.6
(n = 67)
4.2 ± 2.1
(n = 15)
3.2 ± 1.5
(n = 14)
3.0 ± 1.0
(n = 28)
2.6 ± 1.4
(n = 10)
p = 0.002
t test
nMPHD = 20
nIGHD = 73
Female 2.4 ± 1.5
(n = 26)
3.4 ± 2.7
(n = 5)
1.9 ± 0.8
(n = 3)
2.2 ± 1.0
(n = 13)
2.3 ± 1.5
(n = 5)
Height SDS at diagnosis (mean ± SD)
Male –3.1 ± 1.4
(n = 68)
–3.9 ± 1.7
(n = 16)
–3.2 ± 1.9
(n = 16)
–2.7 ± 0.8
(n = 16)
–2.9 ± 0.6
(n = 16)
p = 0.009
Mann-Whitney U test
nMPHD = 21
nIGHD = 75
Female –3.4 ± 1.5
(n = 28)
–4.7 ± 3.2
(n = 5)
–3.8 ± 0.2
(n = 14)
–2.9 ± 0.8
(n = 28)
–3.2 ± 0.7
(n = 10)
Final height, cm (mean ± SD)
Male 169 ± 10
(n = 50)
172 ± 10
(n = 11)
167 ± 14
(n = 12)
169 ± 8
(n = 21)
168 ± 5
(n = 6)
p = 0.580 
t test
nMPHD = 15
nIGHD = 54
Female 156 ± 7
(n = 19)
153 ± 11
(n = 4)
156 ± 6.4
(n = 2)
158 ± 8
(n = 8)
154 ± 2
(n = 5)
Height SDS at end of therapy (mean ± SD)
Male –1.5 ± 1.3
(n = 61)
–0.9 ± 1.5
(n = 14)
–1.7 ± 1.9
(n = 13)
–1.6 ± 1.1
(n = 24)
–1.9 ± 0.7
(n = 10)
p = 0.112
Mann-Whitney U test
nMPHD = 18
nIGHD = 68
Female –2.0 ± 1.3
(n = 25)
–2.6 ± 1.5
(n = 4)
–2.7 ± 1.6
(n = 3)
–1.5 ± 1.3
(n = 12)
–2.1 ± 0.8
(n = 6)
Final height SDS (mean ± SD)
Male –1.3 ± 1.3
(n = 50)
–1.0 ± 1.4
(n = 11)
–1.5 ± 1.9
(n = 12)
–1.3 ± 1.1
(n = 21)
–1.4 ± 0.7
(n = 6)
p = 0.883
t test
nMPHD = 15
nIGHD = 54
Female –1.5 ± 1.2
(n = 19)
–2.0 ± 1.9
(n = 4)
–1.4 ± 1.2
(n = 2)
–1.0 ± 1.3
(n = 8)
–1.8 ± 0.4
(n = 5)
Height SDS gain during GH therapy (mean ± SD)
Male 1.6 ± 1.2
(n = 61)
2.7 ± 1.6
(n = 14)
1.6 ± 0.7
(n = 13)
1.3 ± 0.9
(n = 24)
1.0 ± 0.7
(n = 10)
p = 0.006
t test
nMPHD = 18
nIGHD = 68
Female 1.3 ± 1.3
(n = 25)
2.0 ± 2.4
(n = 4)
1.0 ± 1.4
(n = 3)
1.2 ± 1.0
(n = 12)
1.1 ± 0.9
(n = 6)
Height SDS gain from start of therapy to final height (mean ± SD)
Male 1.9 ± 1.2
(n = 47)
2.9 ± 1.7
(n = 11)
1.8 ± 0.7
(n = 12)
1.6 ± 0.8
(n = 19)
1.3 ± 0.9
(n = 5)
p = 0.010
t test
nMPHD = 14
nIGHD = 51
Female 2.0 ± 1.3
(n = 18)
3.5 ± 2.2
(n = 3)
2.3 ± 0.9
(n = 2)
1.7 ± 1.1
(n = 8)
1.5 ± 0.7
(n = 5)
Genetic TH, cm (mean ± SD) and percentage of patients who reached TH
Male 173 ± 6.2
(n = 68)
80.7%
(46/57)
64.3%
(9/14)
83.3%
(10/12)
87.0%
(20/23)
87.5%
(7/8)
p < 0.001
Fisher’s exact test
nMPHD = 18
nIGHD = 60
Female 159 ± 3.7
(n = 28)
76.2%
(16/21)
75.0%
(3/4)
50.0%
(1/2)
80.0%
(8/10)
80.0%
(4/5)
 Table 1.  GH replacement in children with IGHD and MPHD: baseline parameters and long-term outcomes
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:2
7:
52
 A
M
 Rohayem/Drechsel/Tittel/Hahn/Pfaeffle/
Huebner
 
 Horm Res Paediatr 2016;86:106–116 
DOI: 10.1159/000448098
110
subjects was lower than the population mean according 
to Reinken and van Oost  [8] , with a mean male TH of
173 ± 7 cm (reference 180 ± 6.5 cm) and a mean female 
TH of 159 ± 5.5 cm (reference 167 ± 5.5 cm).
 The adult height of two patients with transfusional 
iron overload was within the TH range in one and below 
it in the other. IGF-1 levels at re-assessment were below 
the normal range in both.
 Analysis of Factors Potentially Influencing Height 
Gain 
 Anthropometric Birth Data. The birth length and birth 
weight of GHD patients born at term were 50 ± 3 cm and 
3,190 ± 470 g for boys (n = 55) and 48 ± 2 cm and 2,950 ± 
500 g for girls (n = 25), with 23 and 14% of GH-deficient 
newborns having a birth length  ≤ –2 SDS. No significant 
association with final height was found (p = 0.16, p = 0.92). 
Table 1 (continued)
All patients with GHD MPHD  IGHD Statistical test
(MPHD vs. IGHD)total partial NSD
Duration of GH therapy, years (mean ± SD)
Male 6.0 ± 4.1
(n = 63)
9.6 ± 5.5
(n = 14)
5.4 ± 3.5
(n = 12)
4.9 ± 2.9
(n = 26)
4.4 ± 2.4
(n = 11)
p < 0.001
Mann-Whitney U test
nMPHD = 18
nIGHD = 70
Female 4.3 ± 2.4
(n = 25)
7.1 ± 0.8
(n = 4)
3.9 ± 3.1
(n = 3)
3.4 ± 2.1
(n = 12)
4.6 ± 2.0
(n = 6)
Start of puberty, years (mean ± SD)
Male 14.5 ± 2.2
(n = 61)
15.7 ± 2.9
(n = 14)
15.2 ± 2.4
(n = 12)
13.8 ± 1.6
(n = 25)
13.5 ± 1.6
(n = 10)
p = 0.001
Mann-Whitney U test
nMPHD = 18
nIGHD = 66
Female 13.0 ± 1.8
(n = 23)
15.5 ± 2.5
(n = 4)
13.5 ± 0.7
(n = 3)
12.4 ± 1.0
(n = 10)
12.4 ± 1.4
(n = 6)
Persistence of GHD in adulthood
Male 20%
(9/44)
89%
(8/9)
0%
(0/9)
5%
(1/20)
0%
(0/6)
p < 0.001
Fisher’s exact test
nMPHD = 9
nIGHD = 49
Female 0%
(0/14)
no patient 0%
(0/1)
0%
(0/8)
0%
(0/5)
0
20
40
60
80
100
%
Total
(n = 70)
1% 3%
Above TH
Upper TH range
Middle TH range
Lower TH range
Below TH
MPHD
(n = 16)
Total GHD
(n = 14)
Partial GHD
(n = 29)
NSD
(n = 11)
23%
24%
38%
19%
21%
21%
17%
24%
18%
36%
20%
31%
34%
21%
27%
18%
29%
29%
13%
31%
 Fig. 2. Final height achieved by GH therapy 
in IGHD and MPHD patients in relation to 
parental TH. 
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None of the patients was large for gestational age at birth; 
24% of our patients were small for gestational age (SGA).
 Chronologic Age at Start of GH Replacement. No asso-
ciation of height SDS gain (p = 0.183) or final height SDS 
(p = 0.633) with chronologic age at start of GH substitu-
tion was found.
 Bone Age at Start of GH Replacement. Bone age retar-
dation was correlated with height SDS gain (Pearson’s
r = 0.366, p = 0.001) and final height SDS (Pearson’s r = 
0.332, p = 0.008). Mean bone age retardation was 3.1 ± 1.5 
years in male and 2.4 ± 1.5 years in female patients ( fig. 3 ) 
and 4.0 ± 2.2 years in MPHD vs. 2.8 ± 1.2 years in IGHD 
patients at the time of GHD diagnosis. The bone ages of 
the IGHD subgroups are detailed in  table 1 .
 Height SDS at the Start of GH Replacement. Height 
SDS at the start of GH replacement correlated with height 
SDS gain (Pearson’s r = –0.492, p < 0.001, n = 86) and with 
final height (Pearson’s r = 0.571, p < 0.00, n = 66).
 Duration of GH Substitution. A correlation was found 
between duration of GH therapy and height SDS gained 
by GH substitution in both male patients (R 2 linear = 0.36, 
Pearson’s r = 0.60, p < 0.001, n = 60) and female patients 
with GHD (R 2 linear = 0.32, Pearson’s r = 0.51, p < 0.001, 
n = 25) ( fig. 4 ).
 Age at Onset of Puberty. No correlation between age at 
onset of puberty and achievement of final height after GH 
therapy was found in either sex. Height SDS gain in sub-
jects who were started on GH before pubertal onset was 
1.4 ± 1.0 vs. 1.0 ± 0.6 (p = 0.25) in those with GH supple-
mentation starting after pubertal onset. Spontaneous pu-
berty occurred later in IGHD boys and girls than in the 
healthy population: mean age at onset of puberty (defined 
by testicular volumes  ≥ 4 ml on each side) in all male sub-
groups of GHD was 14.5 years (vs. 12 years reported for 
healthy boys)  [9] . Likewise, spontaneous puberty (de-
fined by Tanner stage B2) was delayed in all female sub-
groups of IGHD, occurring at a mean age of 13.5 years 
(vs. 10.9 years in the reference population), mean age at 
menarche being 14.5 years (vs. 13.4 years in the reference 
population)  [9] . Puberty started later in total IGHD than 
in partial IGHD patients of either sex (males with total/
partial IGHD: 14.5/14.0 years; females with total/partial 
IGHD: 13.7/12.5 years). Puberty had to be hormonally 
induced in all patients with MPHD.
 GH Preparations. Before 1984, patients with GHD were 
treated with pGH (n = 21), afterwards rGH was used (n = 
75). Patients with replacement initiated before 1984 had 
more severe height SDS deviations from the mean of the 
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reference population than patients treated afterwards 
(median –3.6 vs. –2.8 SDS), and their bone age was more 
severely retarded (–4.0 ± 2.1 vs. –2.8 ± 1.3 years). Mean 
height gain per year was +0.35 SDS with pGH and +0.29 
SDS with rGH, but with no significant differences con-
cerning overall height SDS gain (1.2 vs. 1.4 SDS, p = 0.214).
 Persistence of GHD into Adulthood 
 At re-assessment all but two patients with MPHD were 
off GH treatment since they had reached adult height. 
Eighty-nine percent of the patients and, among these, 
55% of the subjects with MPHD had not consulted endo-
crine services during adulthood. Low IGF-1 levels (<–2 
SDS) at re-assessment were found in 7/9 MPHD patients; 
two subjects had levels in the normal range because of 
ongoing GH replacement. In patients with previous total 
IGHD, 40% had decreased IGF-1 levels, whereas patients 
with previous partial IGHD and patients with former 
NSD had decreased levels in 22 and 9%, respectively 
( fig. 5 ). Only 47% of patients with low IGF-1 levels had an 
insufficient rise of GH levels after GHRH-arginine stimu-
lation. Considering the results of 18 additional patients 
with previously performed GH stimulation tests at an 
adult age, overall severe GHD persistence rates into adult-
hood were 19% (9/47) in the IGHD cohort (22% in pa-
tients with total IGHD, 5% in those with partial IGHD 
and 0% in those with NSD). In contrast, GHD persisted 
in 8/9 (89%) of the subjects with MPHD.
 Prevalence of Associated Hormone Deficiencies 
 Out of 7 MPHD patients without iron overload, 6 
(86%) had LH/FSH deficiency, 6 (86%) TSH deficiency 
and 3 (43%) prolactin deficiency. ACTH secretion was 
compromised in 3 (43%) patients. All 3 MPHD patients 
with  PROP1 mutations were affected by GH, LH/FSH 
and TSH deficiency, 2/3 by additional prolactin deficien-
cy and 1/3 by ACTH deficiency. In two patients with 
transfusional iron overload, primary hypothyroidism 
and secondary hypogonadism developed during adoles-
cence, ‘bronze’ diabetes and hypoparathyroidism during 
early adulthood. None of the patients with IGHD had 
developed further pituitary deficiencies during adult-
hood.
 Genetic Screening Results 
 In one of 41 IGHD patients (2%) a  GH1 mutation was 
detected, whereas  PROP1 mutations were found to be as-
sociated with MPHD in 3/7 (43%) patients. The mutation 
associated with IGHD was a heterozygous splice site mu-
tation (c.IVS3 + 5A → G) in the  GH1 gene, compatible 
with the phenotype of IGHD type II. In three MPHD pa-
tients from two families the mutation c.150delA was de-
tected in  PROP1 , resulting in a shift of the reading frame 
and a premature stop in position 109 (p.Ser109Ter). In 
one patient, this mutation was homozygous. In two broth-
ers, this mutation was associated with a 2-bp deletion 
c.296delGA (c.301_302delGA).
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 Pituitary MRI 
 In two MPHD patients siderosis of the pituitary due to 
iron overload was visualised. The anterior pituitary gland 
was hypoplastic on MRI in the other 5/7 (71%) MPHD 
subjects, the posterior pituitary was ectopic in 3/7 (43%) 
and the stalk invisible in 5/7 (71%) ( fig. 6 ). The anterior 
pituitary was small in 7/40 (18%) available imaging re-
sults of IGHD patients, whereas the posterior pituitary 
gland was eutopic with a normal pituitary stalk.
 Discussion 
 The results of our study confirm previous findings that 
GH replacement during childhood is effective in normal-
ising linear growth. The absolute height SDS gain of
1.6 ± 0.8 observed in our GHD patients and the final 
height SDS of –1.4 ± 1.2 were similar to the results of a 
large French GHD cohort  [10] with a height SDS gain of 
1.1 ± 0.9 and a final height SDS of –1.6 ± 0.9, and very 
similar to the results of a small Belgian study  [11] . The 
mean final height SDS of our GHD boys (–1.3 ± 1.3) was 
identical to that of boys in a large US cohort  [12] who had 
a final height SDS of –1.3 ± 1.0. The girls of both cohorts 
had similar final height SDS (–1.5 ± 1.2 in ours vs. –1.6 ± 
0.9 in theirs). When differentiating between MPHD and 
IGHD, our medians for height SDS immediately after 
stopping GH treatment were higher, with –0.4 SDS for 
MPHD boys compared to –0.7 SDS for Caucasian MPHD 
boys in the large international KIGS database  [13] . The 
median height SDS immediately after stopping GH sub-
stitution in our IGHD patients was lower than that of the 
Caucasian KIGS cohort (–1.5/–1.8 in our boys/girls vs. 
–0.8/–1.0 in KIGS), which can be explained by more se-
vere initial height SDS deviations from the reference 
mean in our patients. However, their median overall 
height gain on GH replacement was similar to that of 
KIGS patients (1.7 vs. 1.6 SDS). The strength of our study 
compared to KIGS, which analysed near-final height 
data, is that we assessed definite final height during adult-
hood. Interestingly, we observed that a large subset of pa-
tients experienced further growth after termination of 
GH therapy. Considering the finding of delayed puberty 
in some of our IGHD patients, this may indicate that in-
dividuals with constitutional delay of growth and puber-
ty (CDGP) could have been diagnosed with GHD as a 
result of GH axis immaturity at the time of standard dy-
namic testing. These patients may not have been catego-
rised as GH-deficient if priming with oestrogens or tes-
tosterone had been performed. However, the recommen-
dation for priming with sex steroids in prepubertal 
subjects before assessment of GH response was included 
in guidelines only after the mid-nineties  [14, 15] .
 Our finding of compromised final height in compari-
son to mid-parental expectations is in line with previous 
study results: final height in our patients was in the range 
of or above the individual parental TH in only 77% of our 
patients (63% in MPHD, 81% in IGHD). In previous 
studies, the difference between final height and TH was 
–0.2 SDS in boys and –0.5 SDS in girls  [13] , while 89% of 
IGHD patients and 81% of MPHD patients achieved their 
genetic height potential  [16] . Unphysiologic hormone 
supplementation or poor adherence to treatment may 
have contributed to lower rates of achievement of paren-
tal TH in MPHD patients.
 The parents of our GHD patients were shorter than the 
population mean, indicating that final height in our GHD 
patient cohort was also influenced by familial short stat-
ure.
 Height SDS and bone age retardation at baseline and 
duration of GH replacement have a significant influence 
on height SDS gain and final height, confirming previous 
findings  [13, 17, 18] and emphasising the importance of 
initiating GH substitution at a young age and providing 
continuous therapy over a long time.
 Surprisingly, no influence on height SDS gain and final 
height was found for age at GH start. Likewise, no influ-
ence was found for anthropometric birth data, onset of 
puberty or use of pGH vs. rGH. The high rate of patients 
born SGA in our cohort (24%), compared to a reported 
incidence of 5.5% among newborns born at term, may 
 Fig. 6. Pituitary morphology on MRI of a patient with MPHD of 
unexplained genetic cause: An ectopic posterior pituitary gland 
(bright spot), a hypoplastic anterior pituitary gland with only a rim 
of pituitary tissue and an invisible pituitary stalk are seen. 
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interfere with our analysis of the impact of birth data on 
outcomes of GH replacement, since different growth pat-
terns have been described for SGA children  [19] . The 
lacking influence of the type of GH used for replacement 
on height SDS gain, despite lower mean final height SDS 
in the pGH group, is in line with previous findings  [20] . 
Due to restricted availability of pGH, stricter criteria for 
GH replacement were applied, leading to a bias of selec-
tion of patients with more important height deviations 
from the reference population at baseline.
 Our study reveals that persistent GHD was an under-
diagnosed condition in adults treated for GHD during 
childhood and that transitional care is essential for this 
patient group. Nevertheless, it is surprising how few of 
the patients in the IGHD cohort had persistent GHD: se-
vere GHD constituting an indication for lifelong substi-
tution  [21] was still present in adulthood in 19% of total 
IGHD patients and in 89% of subjects with MPHD, re-
sulting in total persistence rates of GHD into adulthood 
of 27% in males and 21% in females. In previous studies, 
these rates varied between 33 and 80%  [22–25] , with one 
group  [26] reporting rates similar to ours. Whether these 
relatively low deficiency persistence rates in IGHD pa-
tients indicate that GH is transient in most cases, or 
whether it indicates overtreatment in patients with an un-
known intrinsic growth potential that is not reflected by 
dynamic GH tests, remains unresolved. We acknowledge 
that the cutoff values used in our study are arbitrary  [27] 
due to the lack of any ‘gold standard’ test for GHD diag-
nosis, and that this problem continues to be unresolved, 
as GHD is a continuum between normality and abnor-
mality.
 In addition, our study underscores that in the major-
ity of patients with sporadic IGHD, the aetiology remains 
unknown. Four familial forms of IGHD have been de-
scribed: autosomal recessive types IA and IB, autosomal 
dominant type II, and X-linked recessive type III. We 
identified a heterozygous mutation of the  GH1 gene in 
only 1 out of 42 IGHD patients; no mutations were found 
in the  GHRHR gene in our patients with IGHD. The  GH1 
gene is located on chromosome 17q22–24, consisting of 
four introns and five exons. The prevalence of mutations 
or deletions in  GH1 is reported to be 12% in patients with 
more severe growth failure and at a younger age  [28] . The 
mutation (c.IVS3 + 5A → G) in our patient causes defec-
tive splicing of the  GH1 mRNA, resulting in a GH isoform 
that is retained in the endoplasmic reticulum and impairs 
GH and other hormonal trafficking  [3] . Fitting the diag-
nostic criteria of IGHD type II, our patient was remark-
able because of his height SDS of –7.1 at diagnosis at age 
15 years and his final height of 132 cm (–6.6 SDS), due to 
delayed pGH treatment from age 16 years until final 
height at age 21 years (with a height SDS gain of only 0.5) 
and delayed puberty occurring at age 20. The non-con-
sanguineous parents of our patient had normal height 
(175/165 cm), indicating a de novo mutation. GHD per-
sisted into adulthood, but had not been replaced. Vari-
ability in the evolution of additional endocrinopathies in 
patients with type II GHD has been described  [3] . Our 
patient did not develop any other hormonal derange-
ments until re-assessment at age 55 years.
 Mutations in  GHRHR causing type IB GHD are recog-
nised as a significant cause of familial GHD in the Indian 
subcontinent. This may explain why no such mutation 
was identified in our German cohort.
 In contrast to the low detection rates in IGHD, in pa-
tients with MPHD of our cohort, we identified mutations 
in the  PROP1 gene in 43%. No mutations in genes coding 
for other transcription factors involved in anterior pitu-
itary development were found, leaving 57% of our MPHD 
patients with unknown aetiology.
 The  PROP1 gene is a ‘paired’-like homeobox gene lo-
cated on chromosome 5q35.3 which encodes the tran-
scription factor PROP-1.  PROP1 (acronym for ‘prophet 
of Pit-1’) is required for the expression of  PIT1 (POU1F1). 
Pit-1-dependent cell lines in the anterior pituitary include 
somatotrophs, lactotrophs and thyrotrophs and variably 
gonadotrophs and corticotrophs  [29] . Both  PROP1 muta-
tions found in our cohort [c.296delGA (c.301_302delGA) 
and c.150delA] induce a shift in the reading frame and a 
premature stop codon at the amino acid serine in position 
107. This results in severely reduced synthesis of the en-
coded protein and explains the hormonal derangements 
found in our patients: 3/3 were affected by GH, LH/FSH 
and TSH deficiency, 2/3 had prolactin and 1/3 ACTH
deficiency. We observed that GH treatment near-nor-
malised final height in patients with  PROP1 mutations, 
confirming the findings of Crone et al.  [30] . The highest 
frequencies of patients affected by  PROP1 mutations 
were reported for East-Central and Eastern Europe  [31] , 
pointing to a founder effect. Most of the mutations iden-
tified so far are represented by just two gene variants: 
c.296delGA (previously referred to as c.301_302delGA) 
and c.150delA  [32] . These typical mutations were also 
found in all three patients with  PROP1 changes in our co-
hort.
 Imaging data showed anterior pituitary gland hypo-
plasia in all MPHD subjects and an ectopic posterior pi-
tuitary in 43%, with an interrupted pituitary stalk in 71%. 
Comparable morphologies were described by Zimmer-
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mann et al.  [33] and Acharya et al.  [34] , with 79/43/43% 
and 82/65/94% of the above-mentioned changes. Initial 
MRI in patients with  PROP1 mutations may reveal an en-
larged pituitary, which usually evolves to hypoplasia over 
time  [35, 36] . Our MRI results indicate that at an adult 
age, hypoplasia of the anterior pituitary gland is the cor-
responding morphologic change on MRI in patients with 
 PROP1 defects. In contrast, the anterior pituitary was 
small in only 7/40 (18%) of IGHD patients, without any 
other abnormalities. In line with this, other groups  [33, 
34, 37] have reported reduced pituitary size in IGHD pa-
tients in 26, 53 and 80%, respectively.
 In two patients, transfusional iron overload with sid-
erosis of the pituitary was found to be the cause of short 
stature and additional endocrine failures. These patients 
suffered from Diamond-Blackfan anaemia. We hypoth-
esise that their longitudinal growth was not only impaired 
at the pituitary level, with compromised GH secretion, 
but also at the hepatic level, with reduced IGF-1 respons-
es to GH replacement.
 Summary and Conclusions 
 Continuous GH replacement performed for 5 years in 
IGHD and for 10 years in MPHD was effective in normal-
ising linear growth in children with GHD. Final heights 
in the range of mid-parental expectations were attained 
in around 80%, with an absolute height gain of +1.6 SDS 
and a relative gain of 0.3 SDS per year of GH substitution. 
Lower parental TH in GH-deficient patients points to a 
contribution of familial short stature. Delayed puberty 
and continued growth after GH termination may indicate 
that GHD and CDGP are overlapping conditions, poten-
tially leading to the misdiagnosis of CDGP as GHD. This 
underlines the need for priming with sex steroids before 
carrying out dynamic testing of GH response in children 
of peripubertal age. While the genetic origin of IGHD re-
mains unidentified in the majority of cases,  PROP1 muta-
tions should be considered in subjects with combined pi-
tuitary hormone deficiencies. Hypoplasia of the anterior 
pituitary gland on MRI is found in both IGHD and 
MPHD; however, if combined with pituitary stalk inter-
ruption or ectopy of the posterior pituitary, evolving mul-
tiple endocrine deficiencies and GHD persistence are 
probable. While IGHD patients are not prone to develop 
further pituitary deficiencies during adulthood and have 
variable rates of GHD persistence, most MPHD patients 
require GH replacement during adulthood. Thorough in-
vestigation of all GHD patients at transition into adult 
care seems advisable to ensure continuous and lifelong 
follow-up of patients with hormone deficiencies.
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